Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells from Prostate Cancer Patient-Derived Xenograft Models.

SERPINE1 circulating tumour cell (CTC) epithelial-mesenchymal plasticity (EMP) kallikrein-related peptidase 3 (KLK3) metastasis patient-derived xenograft (PDX) plasminogen activator inhibitor-1 (PAI-1) prostate cancer prostate-specific antigen (PSA)

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
01 Jun 2021
Historique:
received: 02 02 2021
revised: 29 03 2021
accepted: 12 04 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Metastasis is the leading cause of cancer-related deaths worldwide. The epithelial-mesenchymal plasticity (EMP) status of primary tumours has relevance to metastatic potential and therapy resistance. Circulating tumour cells (CTCs) provide a window into the metastatic process, and molecular characterisation of CTCs in comparison to their primary tumours could lead to a better understanding of the mechanisms involved in the metastatic cascade. In this study, paired blood and tumour samples were collected from four prostate cancer patient-derived xenograft (PDX) models (BM18, LuCaP70, LuCaP96, LuCaP105) and assessed using an EMP-focused, 42 gene human-specific, nested quantitative RT-PCR assay. CTC burden varied amongst the various xenograft models with LuCaP96 having the highest number of CTCs per mouse (mean: 704; median: 31) followed by BM18 (mean: 101; median: 21), LuCaP70 (mean: 73; median: 16) and LuCaP105 (mean: 57; median: 6). A significant relationship was observed between tumour size and CTC number (

Identifiants

pubmed: 34206049
pii: cancers13112750
doi: 10.3390/cancers13112750
pmc: PMC8198708
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Endocr Relat Cancer. 2005 Sep;12(3):631-43
pubmed: 16172196
Clin Chem. 2019 Jan;65(1):87-99
pubmed: 30602476
Comp Med. 2015 Apr;65(2):96-113
pubmed: 25926395
PLoS One. 2014 Jan 08;9(1):e85264
pubmed: 24416373
Cancer Res. 1992 Mar 15;52(6):1399-405
pubmed: 1540948
Biol Chem. 2006 Jun;387(6):653-63
pubmed: 16800726
Sci Transl Med. 2012 Mar 28;4(127):127rv3
pubmed: 22461644
Adv Exp Med Biol. 2018;1100:47-53
pubmed: 30411259
Cancers (Basel). 2019 Jul 13;11(7):
pubmed: 31337040
Mol Oncol. 2016 Mar;10(3):418-30
pubmed: 26809472
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Semin Thromb Hemost. 2007 Feb;33(1):87-99
pubmed: 17253195
Am J Pathol. 1997 Feb;150(2):455-9
pubmed: 9033261
Cancer Res. 2003 May 1;63(9):2306-11
pubmed: 12727854
Front Oncol. 2014 Dec 23;4:370
pubmed: 25566507
Cancer Res. 2001 Jul 15;61(14):5587-94
pubmed: 11454712
Contemp Oncol (Pozn). 2015;19(4):265-70
pubmed: 26557772
Transl Androl Urol. 2013 Sep 1;2(3):202-211
pubmed: 25346895
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
BMC Cancer. 2013 Mar 22;13:145
pubmed: 23522088
J Urol. 2020 Jun;203(6):1128-1134
pubmed: 31845840
BJU Int. 2017 Nov;120(5B):E30-E44
pubmed: 27539393
Int J Mol Sci. 2018 Mar 19;19(3):
pubmed: 29562686
Cancers (Basel). 2019 Mar 18;11(3):
pubmed: 30889898
ACS Nano. 2013 Jan 22;7(1):566-75
pubmed: 23194329
BMC Cancer. 2019 Mar 12;19(1):220
pubmed: 30871481
Prostate. 2005 Sep 15;65(1):35-43
pubmed: 15800936
Curr Pharm Des. 2014;20(33):5298-308
pubmed: 24479797
Clin Exp Metastasis. 2019 Aug;36(4):393-409
pubmed: 31190270
Dev Dyn. 2018 Mar;247(3):432-450
pubmed: 28407379
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Sci Transl Med. 2016 Oct 19;8(361):361ra138
pubmed: 27798263
Int J Mol Sci. 2019 Apr 18;20(8):
pubmed: 31003475
Adv Exp Med Biol. 2018;1095:101-110
pubmed: 30229551
Clin Cancer Res. 2016 Feb 1;22(3):670-9
pubmed: 26490309
Front Oncol. 2017 Jan 27;7:6
pubmed: 28191452
Prostate. 2013 Jun;73(8):813-26
pubmed: 23280481
Cells Tissues Organs. 2007;185(1-3):111-5
pubmed: 17587816
Nat Rev Cancer. 2019 Dec;19(12):716-732
pubmed: 31666716
Clin Dev Immunol. 2012;2012:708036
pubmed: 22693526
Nature. 2019 Feb;566(7745):553-557
pubmed: 30728496
Cancer Res. 2007 Dec 15;67(24):11721-31
pubmed: 18089802
Nat Rev Cancer. 2011 Apr;11(4):254-67
pubmed: 21390059
Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995
pubmed: 16024595
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Breast Cancer Res. 2015 Jan 09;17:3
pubmed: 25572662
BJU Int. 2020 Jul;126(1):65-72
pubmed: 32383524
Blood. 2019 May 16;133(20):2186-2197
pubmed: 30898858
Eur Urol. 2007 Apr;51(4):940-7; discussion 947-8
pubmed: 17125912
Cancer Res. 2006 Dec 1;66(23):11271-8
pubmed: 17145872
Clin Cancer Res. 2007 Dec 1;13(23):7053-8
pubmed: 18056182
Cancer Metastasis Rev. 2019 Sep;38(3):483-492
pubmed: 31734763
Cell Metab. 2015 Oct 6;22(4):590-605
pubmed: 26365176
Breast Cancer Res Treat. 2017 Jan;161(1):83-94
pubmed: 27771841
Development. 2005 Jul;132(14):3151-61
pubmed: 15983400
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
Urology. 1999 May;53(5):939-44
pubmed: 10223487
Science. 2015 Sep 18;349(6254):1351-6
pubmed: 26383955
F1000Res. 2017 Aug 14;6:
pubmed: 28868131
Mol Cancer. 2014 Feb 24;13:37
pubmed: 24565133
Eur Ann Otorhinolaryngol Head Neck Dis. 2020 May;137(3):235
pubmed: 31917145
Oncotarget. 2018 Nov 2;9(86):35705-35716
pubmed: 30479699
Oncotarget. 2017 May 23;8(21):35376-35389
pubmed: 28430640
Genome Med. 2020 Mar 19;12(1):31
pubmed: 32192534
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21677-82
pubmed: 21098274
J Physiol. 1973 Jan;228(2):279-84
pubmed: 4687099
Prostate. 2018 Dec;78(16):1262-1282
pubmed: 30073676
Biomed Pharmacother. 2018 Sep;105:83-94
pubmed: 29852393
Breast Cancer Res. 2018 Jan 02;20(1):2
pubmed: 29291741
Oncology. 2016;91(1):48-54
pubmed: 27256106
Biomed J. 2020 Feb;43(1):18-23
pubmed: 32200952
Cell Rep. 2014 Sep 25;8(6):1905-1918
pubmed: 25242334
Cells Tissues Organs. 2021 Apr 26;:1-24
pubmed: 33902034
Br J Cancer. 2012 May 22;106(11):1790-7
pubmed: 22538972
Oncol Lett. 2019 Jan;17(1):3-10
pubmed: 30655732
Cancers (Basel). 2020 Jan 09;12(1):
pubmed: 31936460
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Sci Rep. 2019 Apr 19;9(1):6314
pubmed: 31004097
Nat Cell Biol. 2014 Oct;16(10):992-1003, 1-15
pubmed: 25241037
Transl Res. 2017 Jul;185:58-84.e15
pubmed: 28506696
Mol Cancer. 2014 Mar 12;13:55
pubmed: 24618337
Cancer Res. 2017 Oct 15;77(20):5687-5698
pubmed: 28819021
J Hematol Oncol. 2017 May 12;10(1):106
pubmed: 28499452
Biomark Res. 2018 Oct 30;6:31
pubmed: 30450210
Int J Cancer. 2019 Mar 15;144(6):1421-1431
pubmed: 30070688
Prostate. 2017 May;77(6):654-671
pubmed: 28156002
J Oncol. 2010;2010:617421
pubmed: 20016752

Auteurs

Sara Hassan (S)

Faculty of Health and Institute of Health & Biomedical Innovation (IHBI), School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane City, QLD 4000, Australia.
Translational Research Institute (TRI), Brisbane, QLD 4102, Australia.

Tony Blick (T)

Faculty of Health and Institute of Health & Biomedical Innovation (IHBI), School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane City, QLD 4000, Australia.
Translational Research Institute (TRI), Brisbane, QLD 4102, Australia.

Erik W Thompson (EW)

Faculty of Health and Institute of Health & Biomedical Innovation (IHBI), School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane City, QLD 4000, Australia.
Translational Research Institute (TRI), Brisbane, QLD 4102, Australia.

Elizabeth D Williams (ED)

Faculty of Health and Institute of Health & Biomedical Innovation (IHBI), School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane City, QLD 4000, Australia.
Translational Research Institute (TRI), Brisbane, QLD 4102, Australia.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Brisbane, QLD 4102, Australia.
Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD 4102, Australia.

Classifications MeSH